KR20220110789A - 칼슘 감지 수용체 효능제 화합물 및 이의 응용 - Google Patents

칼슘 감지 수용체 효능제 화합물 및 이의 응용 Download PDF

Info

Publication number
KR20220110789A
KR20220110789A KR1020227022472A KR20227022472A KR20220110789A KR 20220110789 A KR20220110789 A KR 20220110789A KR 1020227022472 A KR1020227022472 A KR 1020227022472A KR 20227022472 A KR20227022472 A KR 20227022472A KR 20220110789 A KR20220110789 A KR 20220110789A
Authority
KR
South Korea
Prior art keywords
xaa
arg
cys
variant
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227022472A
Other languages
English (en)
Korean (ko)
Inventor
팡저우 우
진 장
페이 가오
란 우
쳉 리아오
레이 왕
Original Assignee
베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 filed Critical 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드
Publication of KR20220110789A publication Critical patent/KR20220110789A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020227022472A 2019-12-09 2020-12-08 칼슘 감지 수용체 효능제 화합물 및 이의 응용 Pending KR20220110789A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911250088.1 2019-12-09
CN201911250088 2019-12-09
PCT/CN2020/134598 WO2021115272A1 (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Publications (1)

Publication Number Publication Date
KR20220110789A true KR20220110789A (ko) 2022-08-09

Family

ID=76328843

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227022472A Pending KR20220110789A (ko) 2019-12-09 2020-12-08 칼슘 감지 수용체 효능제 화합물 및 이의 응용

Country Status (11)

Country Link
US (1) US20230041996A1 (https=)
EP (1) EP4091623A4 (https=)
JP (1) JP7796013B2 (https=)
KR (1) KR20220110789A (https=)
CN (2) CN114222578B (https=)
AU (1) AU2020399030B2 (https=)
BR (1) BR112022011127A2 (https=)
CA (1) CA3159744A1 (https=)
MX (1) MX2022006892A (https=)
TW (1) TW202122410A (https=)
WO (1) WO2021115272A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022257940A1 (zh) * 2021-06-08 2022-12-15 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
EP4353248A4 (en) * 2021-06-08 2024-10-23 Beijing Tuo Jie Biopharmaceutical Co. Ltd. CALCIUM-SENSITIVE RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407097A (pt) * 2003-04-23 2006-01-24 Japan Tobacco Inc Antagonista do casr
US8999932B2 (en) * 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
EP2643292A1 (en) * 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
JP2014508103A (ja) * 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
HRP20161566T1 (hr) * 2011-06-08 2017-02-24 Kai Pharmaceuticals, Inc. Terapijski agensi za reguliranje serumskog fosfora
CN109985228A (zh) * 2011-11-10 2019-07-09 凯伊药品公司 拟钙剂及其使用方法

Also Published As

Publication number Publication date
CN114222578B (zh) 2024-06-25
AU2020399030B2 (en) 2026-04-09
CN118496313A (zh) 2024-08-16
AU2020399030A1 (en) 2022-06-23
CN114222578A (zh) 2022-03-22
TW202122410A (zh) 2021-06-16
BR112022011127A2 (pt) 2022-08-23
JP2023504904A (ja) 2023-02-07
EP4091623A1 (en) 2022-11-23
WO2021115272A1 (zh) 2021-06-17
EP4091623A4 (en) 2024-01-03
JP7796013B2 (ja) 2026-01-08
CA3159744A1 (en) 2021-06-17
MX2022006892A (es) 2022-10-07
US20230041996A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
JP5315372B2 (ja) Ｃｘｃｒ４拮抗薬およびその用途
KR20210031533A (ko) Gip/glp1 공효능제 화합물
CN113563423A (zh) 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
PT2213680E (pt) Péptidos que possuem uma atividade farmacológica para o tratamento de distúrbios associados à migração de células alteradas, tais como o cancro
CA3091993A1 (en) Compstatin analogues and their medical uses
EP3184541A1 (en) Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs
KR20220066287A (ko) 콤프스타틴 유사체 및 이의 의약 용도
JP7796013B2 (ja) カルシウム感知受容体アゴニスト化合物及びその使用
EP1422240A2 (en) Analogs of nociceptin
US20230090247A1 (en) Molecules targeting ras protein
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
EP2460826B1 (en) Motilin-like peptide compound having transmucosal absorbability imparted thereto
JP2949129B2 (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
CA2405704C (en) Bombesin analogs for treatment of cancer
JP2021080219A (ja) Ｍｍｐ２阻害作用を有する糖鎖付加ポリペプチド
RU2827834C1 (ru) Соединение, представляющее собой агонист кальций-чувствительного рецептора, и его применение
EP0101929A1 (en) Polypeptide-diesters, their production and use
WO2022257940A1 (zh) 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
HK40069562B (zh) 钙敏感受体激动剂化合物及其应用
HK40069562A (en) Calcium-sensing receptor agonist compound and application thereof
JP4781621B2 (ja) Ｃｘｃｒ４拮抗薬およびその用途
US20240269227A1 (en) Calcium-sensing receptor agonist composition and application thereof
EA049126B1 (ru) Аналоги компстатина и пути их медицинского применения
EA048422B1 (ru) Соединения-коагонисты gip/glp1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000